{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:56:13Z","timestamp":1761710173178,"version":"3.44.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40256-025-00728-x","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T04:36:37Z","timestamp":1743827797000},"page":"667-679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Geographic and Racial Variation in Oral Anticoagulant (OAC) Treatment Among Commercially Insured Patients with Non-valvular Atrial Fibrillation (NVAF) in the United States"],"prefix":"10.1007","volume":"25","author":[{"given":"Brett D.","family":"Atwater","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risho","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashi","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustina","family":"Ogbonnaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amiee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nipun","family":"Atreja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Russ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serina","family":"Deeba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dionne M.","family":"Hines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"1","key":"728_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","volume":"127","author":"J Kornej","year":"2020","unstructured":"Kornej J, Borschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127(1):4\u201320. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.316340.","journal-title":"Circ Res"},{"issue":"24","key":"728_CR2","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.jacc.2018.04.013","volume":"71","author":"M Alkhouli","year":"2018","unstructured":"Alkhouli M, Noseworthy PA, Rihal CS, Holmes DR Jr. Stroke prevention in nonvalvular atrial fibrillation: a stakeholder perspective. J Am Coll Cardiol. 2018;71(24):2790\u2013801. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.013.","journal-title":"J Am Coll Cardiol"},{"key":"728_CR3","doi-asserted-by":"publisher","first-page":"107602962095255","DOI":"10.1177\/1076029620952550","volume":"26","author":"H Saeed","year":"2020","unstructured":"Saeed H, Ovalle OG, Bokhary U, et al. National physician survey for nonvalvular atrial fibrillation (NVAF) anticoagulation comparing knowledge, attitudes and practice of cardiologist to PCPs. Clin Appl Thromb Hemost. 2020;26:1076029620952550. https:\/\/doi.org\/10.1177\/1076029620952550.","journal-title":"Clin Appl Thromb Hemost"},{"key":"728_CR4","doi-asserted-by":"publisher","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2024 Jan 2;149(1):e167. https:\/\/doi.org\/10.1161\/CIR.0000000000001207] [published correction appears in Circulation. 2024 Feb 27;149(9):e936. https:\/\/doi.org\/10.1161\/CIR.0000000000001218] [published correction appears in Circulation. 2024 Jun 11;149(24):e1413. https:\/\/doi.org\/10.1161\/CIR.0000000000001263].\u00a0Circulation. 2024;149(1):e1\u201356. https:\/\/doi.org\/10.1161\/CIR.0000000000001193.","DOI":"10.1161\/CIR.0000000000001207"},{"issue":"3","key":"728_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","volume":"43","author":"A Zirlik","year":"2017","unstructured":"Zirlik A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis. 2017;43(3):365\u201379. https:\/\/doi.org\/10.1007\/s11239-016-1446-0.","journal-title":"J Thromb Thrombolysis"},{"issue":"24","key":"728_CR6","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1016\/j.jacc.2019.10.040","volume":"74","author":"M Alkhouli","year":"2019","unstructured":"Alkhouli M, Friedman PA. Ischemic stroke risk in patients with nonvalvular atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol. 2019;74(24):3050\u201365. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.040.","journal-title":"J Am Coll Cardiol"},{"key":"728_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002776","author":"L Di Biase","year":"2016","unstructured":"Di Biase L. Use of direct oral anticoagulants in patients with atrial fibrillation and valvular heart lesions. J Am Heart Assoc. 2016. https:\/\/doi.org\/10.1161\/JAHA.115.002776.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"728_CR8","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1007\/s11606-020-06180-8","volume":"35","author":"M Bradley","year":"2020","unstructured":"Bradley M, Welch EC, Eworuke E, Graham DJ, Zhang R, Huang TY. Risk of stroke and bleeding in atrial fibrillation treated with apixaban compared with warfarin. J Gen Intern Med. 2020;35(12):3597\u2013604. https:\/\/doi.org\/10.1007\/s11606-020-06180-8.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"728_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","volume":"145","author":"AP Carnicelli","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056355.","journal-title":"Circulation"},{"issue":"12","key":"728_CR10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"issue":"22","key":"728_CR11","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907.","journal-title":"N Engl J Med"},{"issue":"11","key":"728_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"issue":"10","key":"728_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"issue":"1","key":"728_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamacardio.2015.0374","volume":"1","author":"JC Hsu","year":"2016","unstructured":"Hsu JC, Maddox TM, Kennedy KF, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE Registry. JAMA Cardiol. 2016;1(1):55\u201362. https:\/\/doi.org\/10.1001\/jamacardio.2015.0374.","journal-title":"JAMA Cardiol."},{"issue":"20","key":"728_CR15","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.jacc.2017.03.540","volume":"69","author":"LN Marzec","year":"2017","unstructured":"Marzec LN, Wang J, Shah ND, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2475\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2017.03.540.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"728_CR16","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1161\/STROKEAHA.117.017683","volume":"48","author":"I Hernandez","year":"2017","unstructured":"Hernandez I, Saba S, Zhang Y. Geographic variation in the use of oral anticoagulation therapy in stroke prevention in atrial fibrillation. Stroke. 2017;48(8):2289\u201391. https:\/\/doi.org\/10.1161\/STROKEAHA.117.017683.","journal-title":"Stroke"},{"key":"728_CR17","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s11239-023-02855-1","volume":"56","author":"BD Atwater","year":"2023","unstructured":"Atwater BD, Di Fusco M, Keshishian A, et al. Geographic variation in clinical outcomes and anticoagulation among Medicare beneficiaries with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2023;56:626\u201334. https:\/\/doi.org\/10.1007\/s11239-023-02855-1.","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"728_CR18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.hroo.2022.11.004","volume":"4","author":"Z Azizi","year":"2023","unstructured":"Azizi Z, Ward AT, Lee DJ, et al. Sociodemographic determinants of oral anticoagulant prescription in patients with atrial fibrillations: findings from the PINNACLE registry using machine learning. Heart Rhythm O2. 2023;4(3):158\u201368. https:\/\/doi.org\/10.1016\/j.hroo.2022.11.004.","journal-title":"Heart Rhythm O2"},{"issue":"1","key":"728_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jnma.2019.10.003","volume":"112","author":"UR Essien","year":"2020","unstructured":"Essien UR, Magnani JW, Chen N, Gellad WF, Fine MJ, Hernandez I. Race\/ethnicity and sex-related differences in direct oral anticoagulant initiation in newly diagnosed atrial fibrillation: a retrospective study of Medicare data. J Natl Med Assoc. 2020;112(1):103\u20138. https:\/\/doi.org\/10.1016\/j.jnma.2019.10.003.","journal-title":"J Natl Med Assoc"},{"key":"728_CR20","unstructured":"\u00a9 2015 Komodo Health, Inc. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission."},{"issue":"23","key":"728_CR21","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071\u2013104. https:\/\/doi.org\/10.1161\/CIR.0000000000000040.","journal-title":"Circulation"},{"issue":"11","key":"728_CR22","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care"},{"issue":"2","key":"728_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263\u201372. https:\/\/doi.org\/10.1378\/chest.09-1584.","journal-title":"Chest"},{"issue":"12","key":"728_CR24","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","volume":"33","author":"L Friberg","year":"2012","unstructured":"Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500\u201310. https:\/\/doi.org\/10.1093\/eurheartj\/ehr488.","journal-title":"Eur Heart J"},{"key":"728_CR25","doi-asserted-by":"publisher","first-page":"757087","DOI":"10.3389\/fcvm.2021.757087","volume":"8","author":"X Gao","year":"2021","unstructured":"Gao X, Cai X, Yang Y, et al. Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med. 2021;8:757087. https:\/\/doi.org\/10.3389\/fcvm.2021.757087.","journal-title":"Front Cardiovasc Med."},{"issue":"12","key":"728_CR26","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/jamacardio.2018.3945","volume":"3","author":"UR Essien","year":"2018","unstructured":"Essien UR, Holmes DN, Jackson LR 2nd, et al. Association of race\/ethnicity with oral anticoagulant use in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiol. 2018;3(12):1174\u201382. https:\/\/doi.org\/10.1001\/jamacardio.2018.3945.","journal-title":"JAMA Cardiol."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00728-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00728-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00728-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T14:08:23Z","timestamp":1756390103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00728-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["728"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00728-x","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"3 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This study was sponsored by Pfizer and Bristol Myers Squibb.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Brett D. Atwater has received research support from Pfizer and Bristol Myers Squibb. Dionne M. Hines, Serina Deeba, and Cristina Russ are employees and shareholders of Pfizer Inc. Amiee Kang and Dong Cheng are employees and shareholders of Bristol Myers Squibb. Risho Singh is an employee of Cencora and was a paid consultant to Pfizer in connection with the development of the study and manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The data that support the findings of this study are not openly available because of sensitivity reasons and licensure agreements.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Brett Atwater, Cristina Russ, and Dong Cheng: methodology, validation, and writing\u2014review and editing. Risho Singh: methodology, validation, visualization, resources, writing\u2014original draft, and project administration. Shashi Parmar: methodology, software, formal analysis, validation, and writing\u2014review. Augustina Ogbonnaya: methodology, resources, formal analysis, validation, and writing\u2014review and editing. Amiee Kang, Nipun Atreja, and Melissa Hagan: conceptualization, methodology, validation, and writing\u2014review and editing. Serina Deeba: validation and writing\u2014review and editing. Dionne Hines: conceptualization, methodology, validation, writing\u2014review and editing, and supervision.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}